Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT326 and Pumitamig in Advanced Non-small Cell Lung Cancer
NCT07111520Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Sep 2025
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of YL202 and pumitamig in non-small cell lung cancer (NSCLC) (25 arms), sponsored by BioNTech SE. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events up to 27 months and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
YL202pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07111520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111520.